In addition to adverse events reported from clinical trials, the following adverse events have been identified during postapproval use of intranasal fluticasone propionate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to fluticasone propionate or a combination of these factors.
Mortuaire, G., de Gabory, L., François, M., Massé, G., Bloch, F., Brion, N., ... Serrano, E. Rebound congestion and rhinitis medicamentosa: Nasal decongestants in clinical practice. (2013, June 1). Critical review of the literature by a medical panel. European Annals of Otorhinolaryngology, Head and Neck Diseases , 130(3), 137-144. Retrieved from https:///#!/content/playContent/1--S1879729612001378?returnurl=http:%2F%%2Fretrieve%2Fpii%2FS1879729612001378%3Fshowall%3Dtrue&referrer=https:%2F%2F .
The most common side effects associated with fluticasone are headache , throat infection, nasal irritation, sneezing , cough , nausea , vomiting . Hypersensitivity reactions such as skin rash , itching , facial swelling, and anaphylaxis may occur. Some children may experience growth suppression when using fluticasone. A bloody nasal discharge ( nosebleed ) and septum perforation may occur. Fungal infection of the nose and throat, glaucoma , and cataracts are also associated with intranasal fluticasone.